12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Erivedge vismodegib regulatory update

EMA's CHMP issued a positive opinion recommending conditional approval of an MAA from Roche for Erivedge vismodegib to treat adults with metastatic or locally advanced basal cell carcinoma (BCC) for whom surgery or radiation are considered inappropriate. The recommendation was based on data from the open-label...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >